- Home
- BROG vs CRBP Comparison
BROG vs CRBP Comparison
Compare BROG & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- CRBP
- Stock Information
- Founded
- BROG 2019
- CRBP 2009
- Country
- BROG United Arab Emirates
- CRBP United States
- Employees
- BROG N/A
- CRBP N/A
- Industry
- BROG Integrated oil Companies
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- CRBP Health Care
- Exchange
- BROG Nasdaq
- CRBP Nasdaq
- Market Cap
- BROG 112.9M
- CRBP 103.6M
- IPO Year
- BROG N/A
- CRBP N/A
- Fundamental
- Price
- BROG $1.30
- CRBP $8.18
- Analyst Decision
- BROG
- CRBP Strong Buy
- Analyst Count
- BROG 0
- CRBP 8
- Target Price
- BROG N/A
- CRBP $61.38
- AVG Volume (30 Days)
- BROG 25.8K
- CRBP 291.7K
- Earning Date
- BROG 03-04-2025
- CRBP 03-11-2025
- Dividend Yield
- BROG N/A
- CRBP N/A
- EPS Growth
- BROG N/A
- CRBP N/A
- EPS
- BROG N/A
- CRBP N/A
- Revenue
- BROG $73,020,415.00
- CRBP N/A
- Revenue This Year
- BROG N/A
- CRBP N/A
- Revenue Next Year
- BROG N/A
- CRBP N/A
- P/E Ratio
- BROG N/A
- CRBP N/A
- Revenue Growth
- BROG N/A
- CRBP N/A
- 52 Week Low
- BROG $0.80
- CRBP $7.64
- 52 Week High
- BROG $6.66
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- BROG 55.10
- CRBP 35.10
- Support Level
- BROG $1.02
- CRBP $7.64
- Resistance Level
- BROG $1.48
- CRBP $9.51
- Average True Range (ATR)
- BROG 0.09
- CRBP 0.84
- MACD
- BROG 0.04
- CRBP -0.05
- Stochastic Oscillator
- BROG 65.91
- CRBP 13.71
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.